Clinical trials: High-Risk Cancer
Breast Cancer Screening and Diagnosis
Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomized Controlled Trial
Women at high risk of breast cancer (BC) should undergo annual magnetic resonance imaging (MRI) and digital mammography (DM) from at least ages 35 to 60.
- Trial name
- CEM (NCT06629896)
- Testing
- Contrast Enhancement Mammography, magnetic resonance imaging (MRI) and digital mammography (DM)
- Where
- Italy
- Volunteers
- 2,200 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Non-muscle Invasive Bladder Cancer
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
The study aims to establish the safety, tolerability, pharmacokinetics (PK), relevant biomarkers, pharmacodynamics (PD) and preliminary anti-tumor activity of the intravesical administration of eciskafusp alfa in combination with…
- Trial name
- NCT06816017
- Testing
- Eciskafusp Alfa, BCG Medac Strain
- Where
- 9 sites in Australia, Italy and 4 more
- Sponsor
- Hoffmann-La Roche
Prostatic Neoplasms
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases…
- Trial name
- NCT02023697
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 391 people
- Sponsor
- Bayer
Carcinoma, Non-small Cell Lung
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
This study will enroll elderly patients with advanced non-small cell lung cancer who are at high risk of developing chemotherapy toxicity (side effects).
- Trial name
- NCT02590003
- Testing
- Carboplatin, Nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Stage I Testicular Non-Seminomatous Germ Cell Tumor
Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours
High-risk stage 1 NSGCTTs are curable with careful surveillance followed by 3 cycles of BEP (bleomycin, etoposide, cisplatin with 500mg/m2 of etoposide per cycle) chemotherapy for the 40-50% of cases experiencing recurrence.
- Trial name
- 111 (NCT01726374)
- Testing
- BEP(500)
- Where
- 35 sites in United Kingdom
- Volunteers
- 246 people
- Sponsor
- Institute of Cancer Research, United Kingdom
B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia and small lymphocytic lymphoma (hereby referred as CLL) are tumors of B cells. A subset of patients categorized as high-risk CLL has a poor clinical outcome when treated with conventional…
- Conditions
- B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Chronic Lymphatic
- Trial name
- NCT03204188
- Testing
- Ibrutinib, Fludarabine, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Carcinoma, Hepatocellular, Liver Neoplasms
RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System
Hepatocellular carcinoma (HCC) is the 9th leading cause of cancer-related death in the US and one of the leading causes of death in patients with cirrhosis.
- Trial name
- NCT02312817
- Testing
- Mailed Outreach Invitation, Mailed Outreach Invitation and Patient Navigation
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- University of Texas Southwestern Medical Center
Invasive Bladder Cancer, Bladder Cancer
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
The standard treatment of muscle invasive bladder cancer is to administer chemotherapy for approximately 3 months then to have surgery to remove the bladder.
- Trial name
- NCT02030574
- Testing
- Gemcitabine and fractionated cisplatin (combination treatment)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Brown University
Prostate Cancer
High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule
This study will investigate the feasibility of using technology of ultrasound guided HDR brachytherapy to focally increase dose to regions within the prostate that are heavily infiltrated with cancer.
- Trial name
- Dosepainting (NCT01605097)
- Testing
- HDR interstitial brachytherapy
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- British Columbia Cancer Agency
Leukemia, Chronic Lymphocytic Leukemia
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
The goal of this clinical research study is to learn if lirilumab in combination with rituximab can help to control either CLL or Small lymphocytic lymphoma (SLL). The safety of the drug combination will also be studied.
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia
- Trial name
- NCT02481297
- Testing
- Lirilumab, Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
Neuroblastoma is a malignant tumor of the sympathetic nervous system. It is the second most common malignant tumor of childhood.
- Trial name
- NCT00670410
- Testing
- Related donor transplant, Cord blood transplant, Busulfan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Breast Cancer, Health Behavior
Effect of Planned Education on Health Beliefs and Fatalism in Women at High Risk of Breast Cancer
Purpose: This project aims to examine the effects of planned education on health beliefs and fatalism in women at high risk of breast cancer.
- Conditions
- Breast Cancer, Health Behavior, Breast Self-Examination
- Trial name
- NCT06690320
- Testing
- IMPLEMENTATION OF A PLANNED EDUCATION PROGRAM ON HEALTH BELIEF MODEL AND FATUALIST TENDENCIES IN WOMEN AT HIGH RISK OF BREAST CANCER
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Ege University
Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
This phase II trial investigates whether proton radiation therapy directed to the prostate tumor, pelvic, and para-aortic lymph nodes, is an effective way to treat patients with high-risk or lymph node positive prostate cancer…
- Conditions
- Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Trial name
- NCT04725903
- Testing
- High-Dose Rate Brachytherapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Multiple Myeloma, Newly Diagnosed
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in…
- Trial name
- CAREMM-005 (NCT07106710)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-Cell Acute Lymphoblastic Leukemia, Adult
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
This is a Phase I/II study of blinatumomab in combination with pembrolizumab in adult patients with relapsed or refractory B-lineage ALL (B-ALL).
- Trial name
- NCT03160079
- Testing
- blinatumomab, pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Glioma
Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG)
The low grade glioma (LGG) is a type of brain tumor which is generally more common in younger age group patients. Most patients with LGG undergo surgery which is mostly incomplete due to concern about loss of function.
- Trial name
- NCT00137488
- Testing
- imaging and angiogenic profiles
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- AHS Cancer Control Alberta
Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
This pilot phase I trial studies how well CPI-613 (6,8-bis[benzylthio]octanoic acid), cytarabine, and mitoxantrone hydrochloride work in treating patients with acute myeloid leukemia or granulocytic sarcoma (a malignant…
- Trial name
- NCT02484391
- Testing
- 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Wake Forest University Health Sciences
Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma
WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer
The goal of this clinical trial is to learn if a special washing treatment used during surgery can help people with pancreatic cancer live longer.
- Conditions
- Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma, Cholangiocarcinoma, Duodenal Adenocarcinoma
- Trial name
- NCT02757859
- Testing
- Pancreatectomy, Lavage
- Where
- United States
- Volunteers
- 845 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
Hypofractionated Whole Pelvic Radiotherapy of the Prostate
This is a phase I feasibility study to evaluate the feasibility of hypofractionated whole pelvis radiotherapy in 35 patients with biopsy-proven intermediate- to high-risk prostate cancer as defined by NCCN risk criteria.
- Trial name
- NCT02546427
- Testing
- Helical TomoTherapy (HT), CyberKnife SBRT, Permanent Prostate Implant (PPI)
- Sponsor
- Albert J. Chang
Breast Cancer
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
RATIONALE: Collecting and storing samples of blood and studying them in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897416
- Testing
- laboratory biomarker analysis
- Volunteers
- 1,452 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.